130,454 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 130,454 shares of the company’s stock, valued at approximately $4,291,000.

A number of other large investors have also modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its stake in Tarsus Pharmaceuticals by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock valued at $6,924,000 after purchasing an additional 29,465 shares during the last quarter. Vanguard Group Inc. increased its stake in Tarsus Pharmaceuticals by 14.5% in the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock valued at $66,398,000 after purchasing an additional 231,131 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Tarsus Pharmaceuticals in the first quarter valued at approximately $12,640,000. Russell Investments Group Ltd. increased its stake in Tarsus Pharmaceuticals by 38,907.8% in the first quarter. Russell Investments Group Ltd. now owns 30,036 shares of the company’s stock valued at $1,092,000 after purchasing an additional 29,959 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in Tarsus Pharmaceuticals in the second quarter valued at approximately $28,904,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $46.40 on Friday. The stock’s 50-day moving average price is $39.00 and its 200 day moving average price is $32.86. Tarsus Pharmaceuticals, Inc. has a 52-week low of $15.60 and a 52-week high of $52.99. The stock has a market capitalization of $1.77 billion, a PE ratio of -12.18 and a beta of 1.00. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Finally, Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.